Practice of clinical pharmacists participating in the diagnosis and treatment for a patient with rhinocerebral mucormycosis with acute myelocytic leukemia
- VernacularTitle:临床药师参与1例急性髓细胞白血病合并鼻脑型毛霉病患者的诊疗实践
- Author:
Chun TAO
1
;
Min SHI
1
;
Yu HUANG
1
;
Yanyu LI
1
;
Yi XIAO
1
Author Information
1. Dept. of Pharmacy，Zigong Fourth People’s Hospital，Sichuan Zigong 643099，China
- Publication Type:Journal Article
- Keywords:
acute myelocytic leukemia;
rhinocerebral
- From:
China Pharmacy
2022;33(20):2534-2539
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for the diagnosis a nd treatment for rhinocerebral mucormycosis complicated with acute myelocytic leukemia . METHODS Clinical pharmacists were involved in the diagnosis and treatment of rhinocerebral mucormycosis complicated with acute myelocytic leukemia . Through literature review ， clinical pharmacists found that mucormycosis was highly likely according to the patient ’s underlying diseases ，clinical manifestations and medication history ，and suggested the doctors to conduct diagnostic examination in a timely manner ，and recommended Amphotericin B liposome for injection 200 mg once a day for targeted treatment . During the administration of amphotericin B liposome ，clinical pharmacists educated and instructed patientand medical staff about the drug use and monitored patient for possible adverse drug reactions through daily pharmaceutical ward round . RESULTS The patient ’s body temperature returned to normal ，infection was controlled ， and there was no intolerable adverse drug reactions during treatment . No recurrence was observed 6 months after amphotericin B liposome was discontinued . CONCLUSIONS For patients with high risk factors of rhinocerebral mucormycosis ，the risk of mucormycosis can be comprehensively judged according to their clinical manifestations ，combined with history of anti -infective drug use and the results of laboratory examination . At the same time of diagnostic examination ，targeted drugs can be empirically used to reduce the mortality . Amphotericin B liposome is the first choice for mucormycosis ，but long -term use and high dose will increase the risk of adverse drug reactions in patients . Early intervention measures should b e taken and medication education should be done for patients to improve their compliance and ensure adequate dosage and course of treatment .
